| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a551af690fdcd54d47f567136dba9366 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-16 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-795
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G83-003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G69-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G69-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-795
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G83-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G69-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G69-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G69-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 |
| filingDate |
1997-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2006-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32633bb5d8e605cb027cfd0495229eaf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e731fcdcd2ced7091372112ac6946331 |
| publicationDate |
2006-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0927217-B1 |
| titleOfInvention |
Angiogenic inhibitory compounds |
| abstract |
For proposes of prophylactic or treatment of diseases related to inappropriate angiogenesis, a compound can be administered that is (i) a linear, non-carbohydrate polymer having a plurality of side chain groups or (ii) a dendrimer having a plurality of terminal groups. At least one of the side chain groups of the linear, non-carbohydrate polymer has an anionic- or cationic-containing moiety bonded or linked thereto. The plurality of terminal groups of the dendrimer has at least one anionic- or cationic-containing moiety bonded or linked thereto. |
| priorityDate |
1996-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |